Nebularine

Identification

Name
Nebularine
Accession Number
DB04440  (EXPT02701)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • N-D-Ribosylpurine
  • Purine nucleoside
  • Purine riboside
Categories
UNII
B8B604PS4P
CAS number
550-33-4
Weight
Average: 252.2267
Monoisotopic: 252.085854892
Chemical Formula
C10H12N4O4
InChI Key
MRWXACSTFXYYMV-FDDDBJFASA-N
InChI
InChI=1S/C10H12N4O4/c15-2-6-7(16)8(17)10(18-6)14-4-13-5-1-11-3-12-9(5)14/h1,3-4,6-8,10,15-17H,2H2/t6-,7-,8-,10-/m1/s1
IUPAC Name
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-(9H-purin-9-yl)oxolane-3,4-diol
SMILES
[H][[email protected]]1(CO)O[[email protected]@]([H])(N2C=NC3=CN=CN=C23)[[email protected]]([H])(O)[[email protected]]1([H])O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UAdenosine deaminaseNot AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Nebularine.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Nebularine.Experimental
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nebularine.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Nebularine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nebularine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Nebularine.Approved, Investigational
CymarinCymarin may decrease the cardiotoxic activities of Nebularine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Nebularine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Nebularine.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Nebularine.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nebularine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nebularine.Approved, Investigational
GitoformateGitoformate may decrease the cardiotoxic activities of Nebularine.Experimental
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Nebularine.Experimental
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Nebularine.Experimental
OleandrinOleandrin may decrease the cardiotoxic activities of Nebularine.Experimental, Investigational
OuabainOuabain may decrease the cardiotoxic activities of Nebularine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Nebularine.Approved, Vet Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Nebularine.Experimental
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Nebularine.Approved
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Nebularine.Experimental
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Nebularine.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C01736
PubChem Compound
68368
PubChem Substance
46507074
ChemSpider
61656
BindingDB
50335291
ChEBI
18255
ChEMBL
CHEMBL1399702
HET
PUR

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)181 °CPhysProp
water solubility1E+005 mg/LMERCK (1989)
Predicted Properties
PropertyValueSource
Water Solubility16.8 mg/mLALOGPS
logP-0.99ALOGPS
logP-1.9ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)3.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area113.52 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity58.18 m3·mol-1ChemAxon
Polarizability23.51 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5193
Blood Brain Barrier+0.8419
Caco-2 permeable-0.87
P-glycoprotein substrateNon-substrate0.7028
P-glycoprotein inhibitor INon-inhibitor0.9767
P-glycoprotein inhibitor IINon-inhibitor0.9111
Renal organic cation transporterNon-inhibitor0.9415
CYP450 2C9 substrateNon-substrate0.812
CYP450 2D6 substrateNon-substrate0.8277
CYP450 3A4 substrateNon-substrate0.5748
CYP450 1A2 substrateNon-inhibitor0.8872
CYP450 2C9 inhibitorNon-inhibitor0.9628
CYP450 2D6 inhibitorNon-inhibitor0.967
CYP450 2C19 inhibitorNon-inhibitor0.9469
CYP450 3A4 inhibitorNon-inhibitor0.9882
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9683
Ames testNon AMES toxic0.876
CarcinogenicityNon-carcinogens0.93
BiodegradationNot ready biodegradable0.5979
Rat acute toxicity2.1732 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9802
hERG inhibition (predictor II)Non-inhibitor0.8942
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0gba-0960000000-02588b36be524da1fbdb
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0940000000-558c13580fe37e7be7cc
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-1900000000-c0a60904cd95924d259f
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dl-8900000000-dece14475c7e39a2463e
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uxr-0790000000-52cdec17cf806f6a8d60
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0900000000-825da67e9ee8ead415d1
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014l-9800000000-eeb587fff62d67752a0c
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0uk9-0690000000-3132e9cf975c9d333807
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-30611d46c742b20458a6
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-bf687a37f1a8fdee4b9f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-0900000000-1ca445719eb772d826e5
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00di-2900000000-d4186191baed33ece266
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-00di-0900000000-fe942a1442dc2ba58705

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine nucleosides. These are compounds comprising a purine base attached to a ribosyl or deoxyribosyl moiety.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Not Available
Direct Parent
Purine nucleosides
Alternative Parents
Glycosylamines / Pentoses / Purines and purine derivatives / Pyrimidines and pyrimidine derivatives / N-substituted imidazoles / Tetrahydrofurans / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds
show 4 more
Substituents
Purine nucleoside / Glycosyl compound / N-glycosyl compound / Pentose monosaccharide / Imidazopyrimidine / Purine / Monosaccharide / N-substituted imidazole / Pyrimidine / Heteroaromatic compound
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
purine ribonucleoside (CHEBI:18255)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Zinc ion binding
Specific Function
Catalyzes the hydrolytic deamination of adenosine and 2-deoxyadenosine. Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, an...
Gene Name
ADA
Uniprot ID
P00813
Uniprot Name
Adenosine deaminase
Molecular Weight
40764.13 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on June 13, 2005 07:24 / Updated on November 09, 2017 03:42